Best fit framework synthesis of qualitative studies on factors associated with medication nonadherence in people with type 2 diabetes using the COM‐B model

Documenti analoghi

• The impacts of undetected nonadherence in phase II, III and post‐marketing clinical trials: An overview
  di: Elise Le Flohic, et al.
  Pubblicazione: (2024)
• Letter to the editor concerning the article: ‘The impacts of undetected nonadherence in phase II, III and post‐marketing clinical trials: An overview’
  di: Tamás Ágh, et al.
  Pubblicazione: (2025)
• A scoping review of disease‐modifying antirheumatic drug nonadherence in rheumatoid arthritis: Measurement, prevalence and implications for clinical practice
  di: Lauren Fraser, et al.
  Pubblicazione: (2025)
• Prevalence of potentially inappropriate medications among newly treated patients with type 2 diabetes in UK primary care
  di: Maria Luisa Faquetti, et al.
  Pubblicazione: (2024)
• Semaglutide use is associated with neuromuscular junction degradation in older adults with type II diabetes mellitus
  di: Rizwan Qaisar, et al.
  Pubblicazione: (2025)